212,427 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 2nd quarter, Holdings Channel reports. The firm purchased 212,427 shares of the company’s stock, valued at approximately $4,797,000.

A number of other large investors also recently modified their holdings of the company. Alliancebernstein L.P. raised its holdings in shares of PROCEPT BioRobotics by 58.6% in the 3rd quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares in the last quarter. Mackenzie Financial Corp increased its holdings in PROCEPT BioRobotics by 8.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock valued at $49,512,000 after buying an additional 118,971 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in PROCEPT BioRobotics by 11.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company’s stock valued at $47,841,000 after buying an additional 155,601 shares in the last quarter. Finally, State Street Corp raised its stake in PROCEPT BioRobotics by 12.4% in the fourth quarter. State Street Corp now owns 1,489,029 shares of the company’s stock valued at $46,845,000 after buying an additional 164,358 shares in the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on PRCT. Citigroup cut PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Truist Financial set a $21.00 target price on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Piper Sandler lowered their price target on PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Finally, UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Hold” and a consensus price target of $28.00.

PROCEPT BioRobotics Stock Up 4.6%

Shares of NASDAQ:PRCT opened at $21.68 on Friday. The stock has a market cap of $1.24 billion, a P/E ratio of -11.18 and a beta of 0.89. The firm has a fifty day moving average price of $20.40 and a 200 day moving average price of $24.20. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a 1-year low of $16.67 and a 1-year high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. Sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

Insider Activity

In related news, CEO Larry L. Wood purchased 23,900 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. The trade was a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold a total of 1,000 shares of company stock worth $28,480 over the last 90 days. Company insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.